companies vertex-pharmaceuticals-inc 
Law 360 M&A
APRIL 10, 2024
Biotechnology company Alpine Immune Sciences Inc., advised by Fenwick & West LLP, on Wednesday revealed that it has agreed to be bought by Vertex Pharmaceuticals Inc., led by Skadden Arps Slate Meagher & Flom LLP, in a $4.9 billion cash deal.
Benzinga
APRIL 11, 2024
On Wednesday, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) agreed to acquire Alpine Immune Sciences Inc (NASDAQ: ALPN ) for $65 per share or approximately $4.9 Vertex has built its business on genetic medicines for cystic fibrosis, which generated almost $10 billion in revenues in 2023. billion in cash.
Law 360 M&A
JULY 11, 2022
Vertex Pharmaceuticals Inc., repped by Skadden, plans to acquire Cooley-steered biotechnology company ViaCyte Inc. for $320 million in a merger that would unite the companies in working to find a cure for Type 1 diabetes, Vertex announced Monday.
Expert insights. Personalized for you.
52 
Let's personalize your content